In a Monday matchup at Mount Abraham Union High School between two Division II field hockey teams that have played hard this fall, but could use more positive results, the host Eagles used a fast ...
Investor's Business Daily on MSN1h
Has Consumer Products Giant Bristol-Myers Squibb Kicked Into High Gear?A Relative Strength Rating upgrade for Bristol Myers Squibb shows improving technical performance. Will it continue?
Bristol-Myers Squibb (BMY) wins FDA nod to expand the U.S. label for its blockbuster immunotherapy Opdivo in lung cancer.
The FDA has approved nivolumab plus chemotherapy as a neoadjuvant treatment for operable stage IIA to IIIB non–small cell ...
Dividend investing can create substantial passive income over time. A conservative example illustrates this potential: ...
WARN notices filed with the state show more job cuts due in the health sector as companies look to cut costs and streamline ...
By leveraging AI, drug developers are moving beyond incremental gains in efficiency and engaging previously undruggable ...
Two strategies to de-escalate treatment for human papillomavirus (HPV)-positive oropharyngeal cancer failed to show ...
Health Care Select Sector SPDR Fund ETF (XLV) outperformed the S&P 500 in Q3 2024. Bristol-Myers led growth while Moderna ...
A New York federal judge has dismissed a $6.4 billion lawsuit against Bristol-Myers Squibb Co., agreeing with counsel for the ...
From Eli Lilly to Karuna Therapeutics to current owner Bristol Myers Squibb, the newly approved schizophrenia drug had quite ...
Over the next three months, the agency could approve a rival to a fast-selling Pfizer heart drug, a much-debated lung cancer medicine and an addition to Vertex's dominant cystic fibrosis business.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback